REAL-2
Regimen
- Experimental
- epirubicin + cisplatin or oxaliplatin + 5FU or capecitabine (ECF/ECX/EOF/EOX, 2x2 factorial)
- Control
- epirubicin + cisplatin + 5FU (ECF, reference arm)
Population
Advanced esophagogastric cancer
Key finding
Capecitabine noninferior to 5FU (HR 0.86); oxaliplatin noninferior to cisplatin (HR 0.92); EOX best arm mOS 11.2 mo vs ECF 9.9 mo (HR 0.80, p=0.02)
Source: PMID 18172173
Timeline
Guideline citations
- NCCN GASTRIC (p.129)
- CSCO GASTRIC 2025 (p.33)⚠️ OCR source